September 30, 2014 4:49 PM ET


Company Overview of Angiogenix, Inc.

Company Overview

Angiogenix, Inc., a biopharmaceutical company, develops therapeutic solutions for chronic vascular disease. Its products include ACCLAIM, a treatment for chronic ischemia; ANGX-1039, a peripheral vascular disease drug therapy for peripheral blood flow; ANGX-3227, a treatment for sickle cell disease; and Vasotrophin, a product for the generation of blood vessels. The company serves cardiovascular disease, peripheral vascular disease, and sickle cell disease markets. Angiogenix, Inc. was founded in 1997 and is headquartered in Burlingame, California.

500 Airport Boulevard

Suite 100

Burlingame, CA 94010

United States

Founded in 1997





Key Executives for Angiogenix, Inc.

Chief Executive Officer and Director
Age: 66
Vice President of Finance and Chief Financial Officer
Age: 67
Vice President of Business Development
Vice President of Pharmaceutical Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Wellington Foods, Inc. United States
Royal Products Inc. United States
Ethicon LLC United States
SmartCells, Inc. United States
Azur Pharma, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Angiogenix, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at